Market Overview

A Peek Into The Market Before The Trading Starts

Related DIS
5 Must-Download Apps Before Visiting Disney World, Universal Studios And More
6 Major Retailers Starting Back-To-School Campaigns
Binge Watching, Sports at Center of Fox Bid for Time Warner (Fox Business)
Related MSI
Follow Goldman with These Equity ETFs - ETF News And Commentary
Benzinga Weekly Preview: Earnings Season Continues With Geopolitical Tensions As A Backdrop

Pre-open movers US stock futures are higher this morning. Futures for the Dow Jones Industrial Average surged 20 points to 12,784.00 and S&P 500 index futures rose 3.20 points to 1,378.90. Nasdaq 100 futures gained 8.75 points to 2,589.25.

A Peek Into Global Markets European markets were mostly higher today. The STOXX Europe 600 Index gained 0.04%, London's FTSE 100 Index rose 0.31%, French CAC 40 Index declined 0.04% and German DAX 30 index gained 0.27%.

Asian markets ended mostly lower, with Japan's Nikkei Stock Average falling 0.93%, China's Shanghai Composite gaining 0.49% and Australia's S&P/ASX 200 dropping 0.28%. Hong Kong's Hang Seng index rose 0.21% and India's Sensex declined 0.07%.

Broker Recommendation Analysts at Citigroup upgraded Walt Disney Company (NYSE: DIS) from “neutral” to “buy.” The target price for Disney has been raised from $50 to $54.

Disney shares dropped 0.13% to $47.00 in pre-market trading.

Breaking news

  • Motorola Solutions (NYSE: MSI), through its strategic investment arm, Motorola Solutions Venture Capital, today announced its investment in TRX Systems. To read the full news, click here.
  • eBay (NASDAQ: EBAY) and AEG announced that they have signed an unprecedented global partnership to facilitate multiple venue sponsorships and technology integrations, designed to create a constantly evolving showcase of world-class digital technologies for the live event experience for fans across the world. To read the full news, click here.
  • Bristol-Myers Squibb Company (NYSE: BMY) announced Sunday new Phase II data demonstrating that the dual regimen of the investigational NS5A replication complex inhibitor daclatasvir (DCV) and the investigational NS3 protease inhibitor asunaprevir (ASV), without interferon or ribavirin, achieved high rates of sustained virologic response 12 weeks post-treatment (SVR12) in patients with genotype 1b (GT1b) hepatitis C virus (HCV) who were prior null responders to alfa interferon and ribavirin (alfa/RBV).To read the full news, click here.
  • Nektar Therapeutics (NASDAQ: NKTR) will host a conference call with investors to discuss the positive Phase 3 clinical results announced by its partner AstraZeneca. To read the full news, click here.

Posted-In: Citigroup US Stock FuturesNews Futures Global Pre-Market Outlook Markets

 

Most Popular

Related Articles (BMY + DIS)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters

Benzinga Professional